$GTBP

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies ...

Original reporting
Business Insider · markets.businessinsider.com
Published Oct 8, 2025, 1:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 9, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies — source image
Decision brief

The 30-second read

$GTBPNeutralMed
01

Why it matters

Progress in clinical trials can serve as a catalyst for stock movement; however, early-phase results are inherently uncertain.

02

Market read

The trial update is relevant for investors in biotech and healthcare sectors, especially those focusing on oncology therapeutics.

03

What to watch

Regulatory hurdles, funding status, and competitive landscape may influence trial outcomes and stock performance.

Timing: short-term (next 1-2 weeks)

Background

GT Biopharma is conducting a Phase 1 trial for GTB-3650 targeting relapsed or refractory CD33-positive hematologic malignancies, an area with significant unmet medical needs.

Company-level read

Ticker impact

$GTBPNeutralMedium confidence
Context

Primary focus of the news is on GT Biopharma's ongoing clinical trial, which directly impacts GTBP stock.

Expected impact

Potential slight upward movement in GTBP stock within the next 1-2 weeks, contingent on trial progress and investor perception.

Evidence & confidence

While clinical trial updates are generally positive, they are preliminary and do not guarantee immediate stock appreciation. Market reaction depends on broader investor sentiment and trial outcomes.

Market effects

Potential positive sentiment in the biotech sector due to ongoing clinical developments.

Limited; primarily affects US-based biotech stocks.

Low; specific to GT Biopharma and related biotech sector.

Counterpoint

Negative trial results or delays could negatively impact GTBP stock, offsetting any positive sentiment.

Key entities

  • GT Biopharma

    Biotech company developing targeted therapies for hematologic malignancies.

  • GTB-3650

    Investigational therapy targeting CD33-positive hematologic cancers.

Related articles

$GTBPLow

EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout - GT Biopharm

GT Biopharma, a clinical-stage immuno-oncology company using its TriKE natural killer cell engager platform, said AI tools rolled out internally have improved discovery and drug engineering productivity. The company plans to advance lead programs GTB-3650 and GTB-5550 through Phase 1 studies this year and use AI for candidate selection, molecular design, and structural modeling. Shares were up 0.38% to $0.48 premarket, per Benzinga Pro.

$UWMCMed

UWM sued for allegedly misleading investors on hedge strategy

Shareholder Doug Bond filed a class action against UWM Holdings in Michigan federal court, alleging securities fraud over disclosures about UWM’s interest rate derivatives hedge tied to its Two Harbors acquisition. The suit covers purchases from March 9 to Aug. 5, citing a $603.2 million derivatives loss and a $2.05 billion Oaktree cash infusion after a March revenue projection.

$BAMedAI 8/10

Pentagon inks deals with Boeing, RTX to boost production of SM-3 components

The Pentagon signed seven-year framework agreements with Boeing and RTX to expand production of Standard Missile-3 components for SM-3 Block IB and Block IIA, including avionics and ejector assemblies Boeing supplies to Raytheon. The deals aim to stabilize supply chains and expand munitions output. Separately, the Missile Defense Agency awarded Raytheon a $745 million contract for Block IIA interceptors.

$BCLIMed

BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q2 2026 results for the quarter ended June 30, 2026. It said it is preparing to start the Phase 3b ENDURANCE study of NurOwn in ALS under an FDA-agreed Special Protocol Assessment, planning about 200 patients. Cash was about $0.2M vs $1.03M a year earlier, with Q2 net loss about $3.9M. The company appointed Peter J. Pitts as Executive Chairman and raised about $400k in private placements.

$MARAMed

Crypto Biz: Bitcoin ETFs Rebound as Crypto Miners Extend AI Pivot

A $116 million Coldcard hardware wallet exploit renewed scrutiny of self-custody as US spot Bitcoin ETFs saw about $1 billion in net inflows for the week, according to Bloomberg. Strategy CEO Phong Le said Strategy will resume Bitcoin accumulation later this year; Riot Platforms reported a 20-year $9 billion compute deal with Anthropic. Trump Media plans to revamp its crypto treasury after a $238 million Q2 net loss.